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ABSTRACT 
We tested the hypothesis that diabetic individuals with fewer glomeruli are at 
increased risk of diabetic nephropathy than individuals with normal glomerular 
number in an experimental model. Female offspring of Wistar rats fed 6% low protein 
diet (LPD) or 18 % normal protein diet (NPD) during pregnancy were studied. 
Streptozotocin diabetes was induced at 12 weeks and animals sacrificed at 40 weeks. 
Non-diabetic LPD animals were of lower birthweight than NPD animals (5.19±0.64 
vs 6.45±0.67 g, p<0.001) and had fewer glomeruli (27402±3137 vs 34203±6471, 
p<0.05). Glomerular volume correlated inversely with glomerular number (r= -0.64, 
p=0.035) but total glomerular filtration surface area was reduced in the LPD animals 
(4770±541 vs 5779±1302 mm2, p=0.05). Other renal structural and functional 
parameters were similar. Glomerular volume and basement membrane width were 
significantly increased in the LPD and NPD diabetic animals compared to their 
respective controls. However, there was no relationship between glomerular number 
and volume (r= -0.38, p=0.03). Podocyte density was lowest in the LPD diabetic 
animals and the area covered by each podocyte was greater in the LPD diabetic group 
(2.40±0.693 x10-3 mm2) compared to the LPD control (1.68±0.374 x10-3 mm2, 
p<0.001) and the NPD diabetic animals (1.71±0.291 x10-3 mm2, p<0.05). Thus a 
decrease in glomerular number with compensatory glomerular hypertrophy is not 
deleterious to renal structure and function. However, when diabetes is superimposed, 
the expected relationship between glomerular number and volume is lost and 
podocyte abnormalities are apparent. In the long term, these may accelerate the 
development of diabetic glomerulosclerosis. 
 
Word count 248 
 3 
KEYWORDS 
Intrauterine environment; glomerular number; diabetic glomerulosclerosis; nephrin; 
podocyte; streptozotocin diabetes 
  
 4 
INTRODUCTION 
The Barker hypothesis suggests that an intra-uterine insult, leading to low birth weight, 
predisposes to the development of chronic diseases such as hypertension, 
cardiovascular disease and diabetes (1,2). Animals of low birth weight (LBW) 
induced by protein deprivation in utero have smaller kidneys with reduced numbers of 
glomeruli compared to animals of normal birth weight (NBW;3,4). Although some 
compensatory hypertrophy of the remaining nephrons occurs, with an increase in 
intraglomerular pressure, it is likely that total glomerular filtration surface area 
remains low. Hypertension is more common in individuals of low birth weight (1,2), 
probably arising because of a reduction in the glomerular filtration surface area (5). 
This combination of reduced glomerular number, reduced filtration surface area and 
intraglomerular and systemic hypertension results in an increased incidence and 
accelerated progression of non-diabetic renal diseases (6,7,8).  
 
Diabetic nephropathy is characterised by progressive rises in urinary albumin 
excretion rate (UAER) and blood pressure, with declining glomerular filtration (GFR) 
and eventually glomerulosclerosis (9). Increased intraglomerular pressure is pivotal 
(10) and probably interacts with the metabolic abnormalities to drive the development 
of glomerulosclerosis. All components of the glomerular filtration barrier are 
susceptible to damage. There is accumulation of basement membrane and mesangial 
matrix, widening and effacement of the foot processes of podocytes, and loss of 
podocytes. The decline in glomerular filtration rate correlates with the reduction in 
glomerular filtration surface area (11).  
 
Although there is a genetic propensity in the development of diabetic nephropathy, 
environmental and intra-uterine factors may also play a role. We hypothesize that 
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individuals of low birth weight, and thus reduced glomerular number with increased 
intraglomerular and systemic hypertension, who develop diabetes will be at increased 
risk of nephropathy which will progress more rapidly than individuals of normal birth 
weight. There is some support for this, in that several studies have shown that Type 1 
diabetic men with nephropathy (12) and men and women with microalbuminuria (13) 
are shorter than their peers without nephropathy, adult height being used as a 
surrogate for low birth weight. To test this hypothesis we have used a rat model of 
low birth weight and reduced glomerular number, achieved by protein deprivation in 
utero. In a short-term study, we have demonstrated previously that the acute renal 
adaptation to diabetes is altered in animals of low birth weight after one week of 
diabetes (14). We now explore the long-term consequences of diabetes in the same 
experimental model of low birth weight/ reduced glomerular number. 
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METHODS 
Animal husbandry 
Animal experiments were carried out in accordance with the 1986 UK Home Office 
Regulations. Female Wistar rats (Charles River, Kent, UK) were fed either 6% (low 
protein diet; LPD) or 18% casein diet (normal protein diet; NPD; Usine 
d’Alimentation Laboratories, France) for one week before timed-mating and during 
pregnancy.  Diets were isocaloric with a similar source of protein, carbohydrate and 
lipid. The LPD diet contained supplemental methionine (0.3 vs 0.23 %).  
Female offspring were weighed at birth and cross-fostered to NPD periparturient 
lactating dams so that the rats were only exposed to LPD in utero. Following weaning, 
at 21 days, rats were housed in cages at 21 ± 2oC with a cycle of 12 h light (0600-
1800 h), and free access to water and standard rat chow.  
 
Pre-diabetes procedures 
Body weight was measured weekly from weaning until 12 weeks of age. UAER and 
fodder consumption were estimated at weeks 4, 8 and 12. Systolic blood pressure 
(SBP) was estimated at the same time points using an indirect tail cuff method. 
 
Diabetes study 
At 12 weeks of age, LPD and NPD rats were randomly assigned to Control (C) or 
Diabetic (D) groups. Diabetes was induced by intravenous injection of streptozotocin, 
50 mg/kg body weight.  During the first week of diabetes, weight and tail vein blood 
glucose [Accutrend meter (Roche Diagnositics, Welwyn Garden City, UK)] were 
measured between 0900 and 1000 h. Thereafter, weight, tail vein blood glucose and 
urinalysis for glucose and ketones were performed weekly with UAER, fodder 
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consumption and SBP estimated every four weeks. At 40 weeks of age (28 weeks 
post-induction of diabetes), tail vein blood was taken for fructosamine and creatinine 
estimation for the calculation of creatinine clearance. 
 
Perfusion fixation 
At 28 weeks post-diabetes, anaesthesia was induced using a cocktail of 1 ml Hypnorm 
(Janssen Pharmeutica, Beerse, Belgium) and 1 ml midazolam (5mg/ml; Roche 
products Ltd, Welwny Garden City, UK) diluted in 2 ml water for injection, at a dose 
of 0.27 ml/100 mg body weight. The right kidney was removed and frozen in liquid 
nitrogen. Total body perfusion was performed using 4% phosphate buffered formalin 
and 1% glutaraldehyde. The left kidney was removed, stripped of its capsule and 
weighed before storage in 4% phosphate buffered formalin at 4oC. Eight kidneys from 
each group were processed for light and electron microscopy. 
 
Light microscopy 
Each left kidney was cut into 2 mm slices using a razor blade fractionator (15). 
Alternate slices were dehydrated in graded alcohol and embedded in methacrylate 
resin. Blocks was serially sectioned at 20µm intervals using a Universal Reichert Jung 
microtome. Every 10th section and its adjacent section was selected for the estimation 
of glomerular number using the disector fractionator technique (16). Sections were 
stained with PAS and viewed using an Olympus light microscope with video camera 
attachment. 
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Estimation of glomerular number 
One section from each pair was designated the reference section and the other the 
look-up section. The reference section was moved systematically in 5 mm steps on the 
microscope stage and each image captured with the camera and Image-Pro software. 
The corresponding areas in the look-up slide were found and the two images viewed 
side by side on the computer screen at a magnification of x85. An unbiased 2-
dimensional counting frame was superimposed on the images and the number of 
glomeruli appearing in the reference but not the look-up section counted. To improve 
efficiency, the roles of the reference and look-up sections were then reversed. The 
total glomerular number (GN) per kidney was then calculated from: 
GN = 1/f1 * 1/f2 * 1/fa *ΣQ-/2 
Where f1 = sampling fraction 1; f2 = sampling fraction 2; fa = sampled area; Q- = 
number of glomeruli counted. The numerical density of glomeruli (NV) was calculated 
from: 
   NV = (ΣQ-/2) / a*t*ΣPf 
Where Pf = points on reference area; a = area represented by Pf; t = section thickness. 
 
Estimation of glomerular volume 
One slide from each pair was selected randomly and areas sampled as above. A grid 
of coarse and fine points was superimposed and the number of coarse points hitting 
the reference area (Pkid) and fine points hitting glomeruli (Pglom) counted. The 
glomerular volume density VV was calculated from: 
  VV = Pglom / Pkid * R where R = ratio of coarse to fine points 
Mean glomerular volume (MGV) was calculated from the formula: 
  MGV = VV / NV 
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Electron microscopy 
Small pieces of cortical tissue (1 mm3) were post-fixed in osmium tetroxide, 
dehydrated in graded alcohol and embedded in epoxy resin. Ultrathin sections were 
taken from three glomeruli per animal, stained with uranyl acetate and lead citrate, 
and examined using a Philips CM100 electron microscope. The whole glomerular 
profile was photographed for the estimation of mesangial volume fraction 
(VVmes/glom) by point counting (17), podocyte number by the method of Weibel (18, 
19) and surface densities by line intercept method (20). To obtain absolute surfaces, 
densities were multiplied by glomerular volume. The surfaces measured were the 
filtration surface (peripheral basement membrane), mesangio-capillary and mesangio-
urinary surfaces. The sum of the filtration and mesangio-urinary surfaces were 
calculated in order to estimate the total surface area of glomerular basement 
membrane (GBM) underlying the podocytes. Higher magnification micrographs were 
systematically randomly sampled for the estimation of GBM width, and foot process 
width (FPW) (17, 21). 
 
Laboratory Methods 
Aliquots of 24 hour urine were stored at –400C before estimating the urine albumin 
concentration by single-antibody radio-immunoassay with polyethylene glycol 
precipitation (22). The intra-assay and inter-assay coefficients of variation were less 
than 5% and 10%, respectively. Serum and urine creatinine were measured by an 
automated Jaffé reaction, with correction for the prevailing glucose concentration. 
Fructosamine was assayed using the Fructosamine Test Plus (Hoffman-La Roche, 
Basel, Switzerland), as described previously (23). 
 10 
 
Real-Time Quantitative PCR (RT-QPCR) 
After homogenization, total cellular RNA was extracted from renal cortical tissue 
using a 6100 Nucleic Acid PrepStation (Applied Biosystems, Foster City, CA, USA). 
Good RNA quality was ensured in all samples on a 0.5 % agarose gel. Reverses 
transcription from RNA to cDNA was performed with a MultiScribe Reverse 
Transcription kit. Each RT-QPCR reaction was performed using 1 µg total RNA and 
25 µl TaqMan Universal PCR MasterMix (4304437 AB) prepared according to 
protocol. The forward, reverse and TaqMan middle primes for rat nephron 
(Rn00575235_ml AB) and 18S (4319413 AB; housekeeping gene) were purchased 
from Applied Biosystems. Forty cycles at 95 oC for 15 seconds and 60 oC for 1 
minute were performed with an ABI Prism 7000 Sequence Detection System from 
Applied Biosystems. All experiments were carried out in triplicate; three readings for 
each individual sample were made and the average calculated. The relative RNA 
amount was calculated as ∆Ct = Ct (target sample) – Ct (18S sample) and the relative 
amount expressed as 2-(∆Ct).  
 
Statistical analyses 
Albumin excretion rate was log transformed before analysis to correct for skewed 
distribution. Values are given as mean±SD or median (range). Comparisons between 
groups were carried out using one-way analysis of variance (ANOVA) with the 
Bonferroni correction for multiple corrections. A two-tailed p value <0.05 was 
considered statistically significant. All analyses were performed using SPSS version 
11. 
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RESULTS  
Effects of Low Protein Diet  - Comparison of Control LPD and Control NPD 
Animals 
LPD animals were of significantly lower birth weight than NPD animals (Table 1) and 
the weight of the LPD control animals remained lower than that of the NPD control 
rats throughout the study (Table 2 and Figure 1a). Fodder consumption, SBP and 
UAER were similar in the LPD and NPD groups throughout (Figure 1c).  Creatinine 
clearance at the end of the study was similar (Table 2).  
Kidney weight and kidney weight:body weight ratio were similar in LPD and NPD 
control animals (Table 3). Glomerular number was significantly reduced in the LPD 
animals (Table 3), with a significant correlation between birth weight and glomerular 
number in the combined cohort of LPD and NPD animals (Figure 2; r=0.5; p=0.002). 
There was also a significant negative correlation between mean glomerular number 
and mean glomerular volume (r=-0.64, p=0.035, Figure 3a). Mean glomerular 
volume, GBM width, volume fraction of mesangium and mesangio-urinary surface 
and the filtration surface area per glomerulus of peripheral GBM were all similar in 
LPD and NPD control animals (Table 3). However, the total glomerular filtration 
surface area per kidney (GBM surface area X number of glomeruli) was lower in the 
LPD animals (4770±541 vs 5779±1302 mm2; p=0.05). 
 
Podocyte number, density and the area covered by each podocyte were similar in 
NPD and LPD control animals, as were foot process width on mesangium and GBM 
and nephrin mRNA. 
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Effects of Diabetes – Comparison of Control and Diabetic Animals within Each 
Diet Group 
Body weight in LPD and NPD diabetic animals was significantly lower, and fodder 
consumption significantly higher, than in their respective control groups (Table 2 and 
Figure 1a). Blood glucose throughout the study (Figure 1b) and serum fructosamine at 
the end of the study (Table 2) were significantly higher than in the control animals. 
UAER increased throughout the study, and creatinine clearance were significantly 
increased in the 2 groups of diabetic animals (Table 2 and Figure 1c). Blood pressure 
did not change. Kidney weight and kidney weight:body weight ratio were higher in 
both diabetic groups (Table 3). Mean glomerular volume was increased in the diabetic 
groups compared to their respective controls (p<0.05) as was GBM width, although 
this difference did not reach statistical significance (p=0.06 for both; Table 3). In 
contrast to the relationship found in non-diabetic animals, there was no correlation 
between glomerular number and mean glomerular volume in the diabetic animals 
(Figure 3b; r= -0.38, p= 0.2). GBM width correlated with UAER at week 28 of 
diabetes in both LPD (r=0.53, p= 0.008) and NPD animals (r= 0.42, p= 0.046). The 
greater mesangio-urinary surface area in the diabetic animals was significant in the 
LPD group only, suggesting that changes were occurring in the mesangium.  
The absolute number of podocytes was not altered by diabetes (Table 3). However, 
because of the increase in glomerular volume, podocyte density was lower (ANOVA 
P=0.024) and the total surface covered by the podocytes greater (ANOVA P=0.046) 
in the diabetic animals, although the differences between individual groups did not 
reach conventional statistical significance. The area covered by each podocyte was 
increased in the LPD diabetic animals compared to their respective control group. 
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Foot process width on mesangium and GBM was similar in diabetic and control 
animals, as was nephrin mRNA. 
 
Interaction of Diabetes and LP: Comparison of LPD and NPD Diabetic Animals 
Body weight was significantly lower in the LPD diabetic animals compared to the 
NPD diabetic animals (Table 2 and Figure 1a). There were no differences in fodder 
consumption, serum fructosamine, blood pressure, UAER, and creatinine clearance 
between LPD and NPD diabetic animals. Kidney weight was significantly lower in 
the LPD diabetic animals, but kidney weight:body weight ratio was similar. By 
design, glomerular number was significantly lower in the LPD diabetic animals. Mean 
glomerular volume was similar (1.84±0.24 vs 1.69±0.22 x106 µm3, p=0.271) and no 
differences were found in GBM width, volume fraction mesangium and mesangio-
urinary surface or podocyte number (138±37 vs 174±35, p=0.095). Podocyte density 
was reduced (ANOVA P=0.024), although the difference in podocyte density between 
the LPD and NPD diabetic animals did not reach significance (95±29 vs 133±35 per 
106 µm3, p=0.305). However, the area covered by each podocyte was significantly 
greater in the LPD diabetic compared to NPD diabetic animals (2.40±0.693 vs 
1.71±0.281 x10-3 mm2, p<0.05). In the LPD diabetic animals, podocyte density (r=-
0.597, p=0.002) and area covered by each podocyte (r=0.481, p=0.017) correlated 
with UAER at 28 weeks diabetes. No such relationships were seen in the NPD 
diabetic animals (density r=-0.255, p=0.24; area r=0.269, p=0.214). Foot process 
width on mesangium and GBM and nephrin mRNA were similar in diabetic LPD and 
NPD animals. 
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In the whole cohort of animals, UAER at 28 weeks diabetes correlated with mean 
glomerular volume (r=0.67, p<0.001) and GBM width (r=0.50, p<0.001). There was 
also a significant relationship between mean glomerular volume and creatinine 
clearance (r=0.48, p<0.05). 
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Discussion 
As expected from previous studies (24), animals fed LPD in utero were of lower birth 
weight and had fewer glomeruli than animals fed NPD. Protein restriction in 
pregnancy is associated with increased apoptosis of mesenchymal cells at the start of 
rat metanephrogenesis, so that fewer precursors are available to differentiate into 
nephrons (25). Angiotensin may also play a role, as renal expression of the 
angiotensin II type 2 receptor is reduced in animals fed LPD in utero, with a greater 
and more prolonged pressor response to infusion of angiotensin II (26).  
Glomerular number was reduced by approximately 20 %.  The interrelationship of 
glomerular number and volume is supported by the correlations between glomerular 
number and mean glomerular volume. Despite this attempt at compensatory 
glomerular hypertrophy, total kidney filtration surface area was reduced in the LPD 
control animals. However, at 40 weeks of age, no deleterious effects were observed 
on renal function or structure. Thus a reduced number of glomeruli is not deleterious 
per se to the kidney, at least for the duration of this study. It is likely that 
intraglomerular pressure is increased in the LPD animals. However, glomeruli appear 
to be able to resist this insult for some time. A parallel may be drawn with renal 
transplant donors, where longitudinal studies have shown no adverse effects in the 
early years after nephrectomy (27) but an increased prevalence of microalbuminuria 
and hypertension after 12-31 years (28). 
 
Individuals of birth weight <2.5 kg are at increased risk of developing end-stage renal 
disease (7,29) or albuminuria (6) compared to those of birth weight >2.5 kg. Low 
birth weight, with fewer glomeruli, may provide a partial explanation for the excess 
end-stage renal disease in African Americans compared to Caucasians (7).  However, 
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a second insult may be necessary before the detrimental effects of the reduced 
nephron mass become apparent. Congenital nephron deficits may interact with 
environmental and genetic factors to generate glomerulosclerosis (30). In children 
with nephrotic syndrome (31) or IgA nephropathy (32), those with intrauterine growth 
retardation had higher blood pressure and more rapidly progressive disease than those 
of normal birth weight.   
 
Our LPD streptozotocin-diabetic animals were subjected to such a second insult. The 
LPD and NPD diabetic animals showed the classical functional and structural changes 
associated with early human and experimental diabetic glomerulosclerosis. UAER, 
creatinine clearance, mean glomerular volume and basement membrane thickness 
were all increased, and mesangio-urinary surface area and volume fraction of 
mesangium non-significantly. Changes in these parameters were generally similar in 
the LPD and NPD diabetic animals. However, podocyte density was lower and the 
average area covered by each podocyte higher in the LPD diabetic animals compared 
to the NPD diabetic group. This would suggest that the podocyte is particularly 
sensitive to the double insult of reduced nephron mass and diabetes.  
 
The podocyte is sensitive to both pressure (stretch) and metabolic perturbations. 
When differentiated mouse podocytes are subjected to mechanical stress, foot 
processes become thin and elongated due to a reversible re-organization of the actin 
cytoskeleton (33). Mechanical stretch also induces changes in cell cycle regulatory 
proteins leading to decreased growth (34) and reduced expression of the β1 subunit of 
the α3β1 integrin in the foot process (35). A reduction in nephron number and the 
induction of diabetes both elevate intraglomerular pressure, so it is likely that 
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intraglomerular pressure in the LPD diabetic animals was significantly higher than in 
the NPD animals. This increased pressure may at least in part account for the changes 
in the podocyte in the LPD diabetic animals.  
 
Hyperglycaemia also has structural and functional effects on podocytes.  In cultured 
cells and in vivo, there is reduced expression of the β1 subunit of the α3β1 integrin 
(35,36), the combination of mechanical stretch and hyperglycaemia having an 
additive effect (36). A reduction in nephrin mRNA and protein has been reported in 
advanced human diabetic nephropathy with proteinuria and hypertension (37,38) and 
in experimental models with both diabetes and hypertension (39,40). Reductions in 
nephrin are much less in patients with microalbuminuria (37) and are not observed in 
animal models without hypertension (39).   Thus the lack of change in nephrin mRNA 
in our current study is not surprising.  
 
Thus hyperglycaemia, in addition to haemodynamic factors, has contributed to the 
podocyte changes seen in our LPD diabetic animals. Significant correlations between 
both podocyte density and the area covered by each podocyte with urine albumin 
excretion were observed only in the LPD animals, suggesting that podocyte damage 
does contribute to the proteinuria of diabetic glomerulosclerosis. Morphological 
changes, including foot process broadening and effacement and eventually a reduction 
in podocyte number are recognized (41-44). 
 
An inverse correlation was observed between glomerular number and mean 
glomerular volume in control animals, a reflection of compensatory enlargement in 
animals with fewer glomeruli in an attempt to increase the total available glomerular 
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filtration surface area.  Such a relationship was not seen in the diabetic animals. This 
suggests that in the LPD animals, glomerular changes had already occurred so that the 
glomerular hypertrophy expected in response to hyperglycaemia was in some way 
attenuated. Over a prolonged period of time, this inability of the glomerulus to expand 
further in response to diabetes may be deleterious, preventing the glomerular tuft to 
accommodate increasing mesangial matrix accumulation. 
 
The finding that animals of low birth weight and thus a reduced number of glomeruli 
develop podocyte abnormalities when diabetes is induced may have implications for 
human diabetes. Indeed, one explanation for the very high prevalence and rapid 
progression of diabetic nephropathy in Pima Indians may be the co-existence of 
glomerulomegaly and glomerulopenia (45). 
 
In conclusion, animals of low birth weight have reduced number of glomeruli and  
total glomerular filtration surface area. However, over the duration of this study, renal 
structural or functional abnormalities did not develop. When a second renal insult, 
diabetes, is added, the expected relationship between glomerular volume and number 
is lost, suggesting that glomerular response to hyperglycaemia is abnormal.  Perhaps 
because of this and the greater increase in intraglomerular pressure, podocyte changes 
are more marked in low birth weight diabetic than normal birth weight animals. 
Podocyte density is decreased and the area covered by each podocyte increased. 
Long-term, this stress on the podocyte may lead to podocyte loss and accelerate the 
development of diabetic glomerulosclerosis
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Figures 
1. Changes in body weight (A), blood glucose (B) and urinary albumin excretion 
rate (C) throughout the study in female offspring of animals fed normal 
protein diet (NPD) or low protein diet (LPD) during pregnancy. Diabetes was 
induced at 12 weeks.  
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2. Relationship of birth weight and glomerular number in female offspring of 
animals fed normal protein diet (NPD) or low protein diet (LPD) during 
pregnancy 
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3. Relationship of glomerular number and mean glomerular volume in control 
and diabetic  groups of female offspring of animals fed normal protein diet or 
low protein diet during pregnancy 
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4. Relationship of podocyte density and urine albumin excretion rate in female 
offspring of animals fed low protein diet (LPD; A) or normal protein diet 
(NPD; B) during pregnancy 
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 Table 1 Pre-Diabetes Data 
 
 Low Protein Diet Normal Protein Diet 
 Control Diabetic Control Diabetic 
ANOVO 
P 
Birthweight (g) 5.19±0.64*** 4.68±0.67*** 6.45±0.67 7.00±0.85 <0.001 
Bodyweight 
(g) at 12 weeks 
233±18.1* 235±13.7* 253±37.7 255±21.7 0.004 
SBP (mmHg) 
at 12 weeks 
122±9 120±10 115±11 118±8 0.180 
UAER  
(mg/24 h) 
0.28  
(0.12-1.45) 
0.46 
(0.12-1.68) 
0.43 
(0.11-1.21) 
0.51  
(0.12-6.96) 
0.164 
 
 
Mean±SD or median (range) 
* P<0.05 vs respective NPD group 
*** P<0.001 vs respective NPD group 
SBP systolic blood pressure 
UAER urine albumin excretion rate 
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Table 2 Metabolic parameters after 28 weeks diabetes (study week 40) 
 
 Low Protein Diet Normal Protein Diet 
 Control Diabetic Control Diabetic 
ANOVO 
P 
Bodyweight (g) 
week 40 
333±19.9* 234±20.8*a 353±56.7 270±30.9a <0.001 
Fodder 
consumption (g) 
21.3±3.6 45.5±5.1a 20.5±3.1 50.7±6.7a <0.001 
Fructosamine 
(mmol/l) 
296±54 362±69a 301±26 396±67a <0.001 
SBP (mmHg) 111±16 110±10 111±11 116±9 0.124 
UAER (mg/24 h) 2.94 
(0.40-68.4) 
27.5a 
(2.51-99.1) 
2.62 
(0.37-45.0) 
14.8a 
(2.35-113.5) 
<0.001 
Serum creatinine 
(µmol/l) 
49±7 45±10 49±6 54±20 0.239 
CrCl (ml/min) 1.5±0.4 2.6±0.6a 1.7±0.3 2.8±1.0a <0.001 
Nephrin mRNA 1.005±0.197  1.542±1.034 1.004±0.150 0.887±0.225 ns 
 
* P<0.05 vs respective NPD group 
a
 P<0.001 vs respective control group 
SBP systolic blood pressure 
UAER urine albumin excretion rate 
CrCl creatinine clearance 
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Table 3 Renal Parameters 
 
 Low Protein Diet Normal Protein Diet 
 Control Diabetic Control Diabetic 
ANOVO 
P 
Kidney weight (g) 0.93±0.08 1.53±0.15*a 1.02±0.17 1.83±0.24a <0.001 
Kidney weight:  
body weight ratio 
0.273± 
0.024 
0.656± 
0.070a 
0.287± 
0.031 
0.672± 
0.062a 
<0.001 
Glomerular 
number 
27402± 
3137* 
26971± 
3540* 
34203± 
6471 
33615± 
2875 
0.009 
Mean glomerular 
volume (x106 µm3) 
1.38±0.23 1.84±0.24a 1.20±0.35 1.69±0.22a 0.002 
GBM width (nm) 263±28 294±13b 272±18 304±26b 0.003 
Vvmes/glom 0.168± 
0.029 
0.181± 
0.022 
0.160± 
0.014 
0.175± 
0.030 
0.393 
Mes-urinary 
surface (mm2) 
0.070± 
0.014 
0.102± 
0.023a 
0.075± 
0.019 
0.094± 
0.020 
0.007 
Podocyte number 157±42 138±37 163±26 174±35 0.283 
Podocyte density 
(/106 µm3) 
136±38 95±29 158±48 133±35 0.024 
Surface underlying 
podocytes (mm2) 
0.252± 
0.030 
0.314± 
0.056 
0.254± 
0.046 
0.294± 
0.057 
0.046 
Area covered by 
each podocyte 
(x103 mm2) 
1.68± 
0.374 
2.40± 
0.693*a 
1.60± 
0.400 
1.71± 
0.281 
0.008 
FPWmes (nm) 490±85 499±41 412±74 464±84 0.124 
FPWgbm (nm) 408±58 472±74 409±46 416±25 0.075 
 
 
 
 
* P<0.05 vs respective NPD group 
a
 P<0.001 vs respective control group 
b
 P=0.06 vs  respective control group 
GBM glomerular basement membrane 
Vvmes/glom volume fraction of mesangium 
Mes-urinary surface mesangio-urinary surface 
FPWmes foot process width on the mesangium 
FPWgbm foot process width on the glomerular basement membrane 
 
 
